Should I buy Gilead Sciences stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Gilead Sciences for over three years. Every month, hundreds of thousands of users in the US trust us to analyze market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our code of ethics, we have never been, and will never be, compensated by Gilead Sciences.

What is Gilead Sciences?

How much is Gilead Sciences stock?

The price of Gilead Sciences stock is rising this week.

Currently, Gilead Sciences is trading at $111.51, with a 24-hour change of -0.20% and a strong weekly gain of +3.81%. The company boasts a market capitalization of $138.71 billion and sees an average volume of 9.24 million shares over the past three months. Its price/earnings ratio stands at 23.47, accompanied by a solid dividend yield of 2.85% and a low beta of 0.31. This stability, along with consistent performance, highlights Gilead Sciences as an attractive opportunity for investors seeking resilient growth potential.

Our full analysis of the Gilead Sciences stock

We have reviewed Gilead Sciences's latest financial results, as well as the stock's performance over the past three years. Integrating diverse analysis—from financial metrics, technical indicators, and market dynamics to a comparative scan of major sector competitors—our proprietary algorithms provide a multifaceted view on this legacy biopharma innovator. So, why might Gilead Sciences stock once again become a strategic entry point into the biotechnology and healthcare innovation sector in 2025?

Recent performance and market context

Gilead Sciences has delivered an impressive turnaround, with its stock climbing over 67% in the past twelve months and recently reaching $111.51 per share (as of July 3, 2025). After a multi-year consolidation period, the last six months saw a robust upward shift (+22%), propelled by positive pipeline developments and renewed growth in the company’s core franchise. The market capitalization now stands at $138.71 billion—a testament to growing investor confidence in Gilead’s resilience. Major catalysts reflect not only internal momentum but a constructive broader market, as the Nasdaq Biotechnology Index rebounds thanks to cooling US inflation, greater regulatory visibility, and renewed risk appetite among both institutional and individual investors.

Gilead’s resurgence reflects its ability to innovate in a changing healthcare landscape. The US regulatory environment has remained constructive, with key FDA approvals for new products like Yeztugo (lenacapavir)—the first six-month, long-acting injectable for HIV prevention. In parallel, the global focus on pandemic preparedness and oncology innovation has enabled biotech leaders like Gilead to secure sales diversification and funding for further R&D. Notably, its selection for the TIME100 most influential companies list in 2025 underscores industry recognition of its scientific and strategic impact.

Technical analysis

Technical signals for Gilead Sciences are unambiguously positive and reinforce the case for a new bullish cycle. The 14-day RSI hovers at a neutral 57.24, leaving ample room for upward movement before approaching overbought territory. The MACD has recently crossed into bullish territory (0.88), signaling renewed momentum, while all short- and long-term moving averages (20, 50, 100, and 200 days) are trending above the current share price.

Support levels have steadily risen—$109.62 now serves as a solid technical floor, while the $114.77 resistance level provides an initial upside target for trend followers. The price remains comfortably above pivotal moving averages, and there are 13 buy signals versus just 1 neutral across widely used technical indicators. These technical factors, combined with increased trading volumes, suggest a favorable environment for both short-term trades and medium-term accumulation.

Short- and medium-term structures point to healthy consolidation following breakout momentum, reducing the risk of sharp corrections. Market structure also indicates strong underlying demand in the $100–$110 price range, offering traders a clear zone for support and a compelling risk/reward setup.

Fundamental analysis

From a fundamental perspective, Gilead Sciences is demonstrating renewed earnings growth, margin expansion, and solid capital management. First-quarter 2025 sales stood at $6.67 billion—stable year-over-year despite sector headwinds—with the flagship Biktarvy HIV therapy driving 7% growth and representing a robust recurring revenue stream. The HIV franchise remains the backbone, while liver disease and oncology segments are showing promising traction and pipeline momentum. Gilead’s oncology advances, particularly with Trodelvy and the Kymera partnership, open substantial new addressable markets.

Profitability is supported by operational leverage: the company posted a notable non-GAAP EPS beat ($1.81 versus a $1.75 consensus). The forward P/E ratio of 14.08 is strikingly attractive versus peers, signaling discounted growth and leaving significant upside in a sector where innovation is often richly rewarded. Moreover, the company’s 2.85% dividend yield remains above average for the US health sector, sweetened by a recent 2.6% increase, reflecting Gilead’s commitment to returning capital to shareholders alongside robust free cash flow generation.

Structurally, Gilead strengthens its profile with a diversified, innovation-driven pipeline, a strong balance sheet ($7.9 billion in cash), and a uniquely dominant position in long-acting and combination HIV therapies. The company remains dedicated to reinvesting in both R&D and accretive partnerships, securing its relevance across multiple therapeutic areas.

Volume and liquidity

A sustained three-month average trading volume of 9.24 million shares ensures deep liquidity and easy access for both institutions and individual investors. High liquidity levels facilitate price discovery and the quick entry/exit required for tactical and strategic positioning.

Gilead Sciences benefits from a float of 1.245 billion shares, making the stock suitable for a broad spectrum of investors and inclusion in major US indices and ETFs. Such liquidity is a strong vote of confidence in the company and often acts as a catalyst for further valuation expansion when positive news or results emerge.

Catalysts and positive outlook

• Regulatory successes: Recent FDA approval of Yeztugo (lenacapavir) positions Gilead as the leader in long-acting HIV prevention, opening new market opportunities and reinforcing its scientific credibility.
• Pipeline progress: Ongoing Phase 3 trials for annual HIV prevention options and expanded indications for oncology assets like Trodelvy suggest sustained growth potential through 2026 and beyond.
• Strategic innovation: The $750 million Kymera partnership in molecular degraders places Gilead on the cutting edge of oncology R&D, echoing sector trends toward precision medicine and high-value biotherapeutics.
• ESG commitment: Not only is Gilead advancing transformative therapies, but its social responsibility efforts and inclusion in the TIME100 list enhance its appeal to a new generation of ESG-focused investors.
• Sector tailwinds: The US biotech industry is experiencing renewed M&A activity, regulatory clarity from the FDA, and increased capital inflows, all amplifying upward momentum for top-tier innovators.

With consensus analyst targets projecting a price of $116.77 (about 4.7% above current levels) and the company continuing to deliver on both innovation and shareholder returns, the outlook for Gilead Sciences remains resoundingly constructive.

Investment strategies

• Short-term positioning:
  Recent breakouts above key resistance and buy signals in technical indicators offer opportunities for tactical entries, especially around established support at $109–$110, with potential to capture momentum to the $114–$120 range.
• Medium-term accumulation:
  The convergence of both pipeline progress and robust dividend policy makes Gilead appealing for those seeking a blend of income and capital appreciation in the next 12–24 months.
• Long-term conviction:
  With a strong lead in antiviral innovation, deep cash reserves, and a forward P/E significantly below sector averages, Gilead appears to be entering a new era of sustained value creation, supported by continued advances in HIV, liver disease, and oncology.

Ideal positioning can be achieved by building exposure during periods of technical consolidation or immediately ahead of clinical trial results and regulatory announcements, when risk-reward ratios are typically most favorable.

Is it the right time to buy Gilead Sciences?

Gilead Sciences combines resilient fundamentals, renewed pipeline momentum, a compelling valuation, and a high level of investor confidence. Its leadership in HIV therapies, disciplined capital allocation, and expanding portfolio in high-growth indications power both stability and long-term upside. Given the bullish technical structure, sustained institutional support, and the powerful array of near-term catalysts, the stock seems to represent an excellent opportunity for investors seeking both growth and defensive attributes in one of biopharma’s global leaders.

With its proven track record of innovation, attractive pricing, and clear signals of a new upward cycle, Gilead Sciences is poised to reward disciplined investors who position early in its next wave of growth. The convergence of technical and fundamental strengths supports a conviction that this blue-chip biotech is about to enter a new bullish phase. Now may be an ideal time to reassess its potential as a strategic, long-term addition to a diversified portfolio seeking robust healthcare innovation and rewarding total returns.

How to Buy Gilead Sciences Stock in the US

Buying Gilead Sciences stock online is a simple and secure process when you use a regulated US broker. Today, investors have two main options: purchasing Gilead Sciences shares outright (spot buying) for long-term holding or trading Gilead Sciences via Contracts for Difference (CFDs) with leverage for more dynamic strategies. Each method has its own costs and risk profile, allowing you to choose the best fit for your goals. To help you make an informed choice, a comprehensive broker comparison tool is available further down the page.

Spot buying

With spot buying, you directly acquire shares of Gilead Sciences and become a genuine shareholder. This method typically involves a fixed commission per order, usually about $5 per trade at major US brokers. You own the actual shares, are eligible for dividends, and can hold them as long as you want.

Gain scenario

If the Gilead Sciences share price is $111.51, you can buy around 8 shares with a $1,000 stake, including a brokerage fee of around $5.

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD trading allows you to speculate on the price movements of Gilead Sciences without owning the actual shares. Instead, you trade contracts with the broker, paying the spread (the difference between buy and sell price) and potentially overnight financing fees if you hold positions for more than a day. There is also the possibility to use leverage, which amplifies both potential gains and risks.

CFD Gain Scenario Example

You open a CFD position on Gilead Sciences shares, with 5x leverage.

This gives you a market exposure of $5,000 for a $1,000 stake.

✔️ Gain scenario:

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Before investing, always compare broker fees and account terms carefully to ensure the method is right for you. The choice between buying actual shares or trading via CFDs depends on your aims: long-term ownership and income, or short-term trading with leverage. For personalized comparisons, don’t forget to use the broker comparison tool included further down the page.

Our 7 tips for buying Gilead Sciences stock

The latest news about Gilead Sciences

Gilead Sciences stock has surged 3.81% in the last week, outpacing the broader biotech sector. This recent uptick comes as the company benefits from positive investor sentiment following significant product approvals and strong technical signals. The NASDAQ-listed Gilead Sciences continues to demonstrate resilience, firmly maintaining its position among top US pharmaceutical equities.

The FDA has approved Yeztugo (lenacapavir) as a new HIV prevention option, boosting Gilead’s market outlook. This first-of-its-kind drug delivers six months of protection per dose, establishing Gilead Sciences as an innovator in HIV care and offering a major commercial advantage for US markets. Analysts anticipate robust adoption in both public and private healthcare settings nationwide.

Gilead Sciences has finalized a $750 million strategic oncology partnership with US-based Kymera Therapeutics. The deal aims to advance development of targeted protein degraders against cancer, reinforcing Gilead’s expansion into oncology and demonstrating its commitment to domestic R&D and enterprise partnerships.

Technical signals are uniformly positive, with all major moving averages supporting a sustained uptrend for Gilead Sciences. Analysts have noted that the stock price is above its 20, 50, 100, and 200-day moving averages, with a bullish MACD signal and a neutral RSI, pointing to further upside potential and robust market momentum in the US context.

Gilead Sciences was named to the TIME100 Most Influential Companies list in 2025, reflecting significant industry and societal impact. This recognition highlights the company’s leadership in biotech innovation and its strong presence in the US healthcare sector, further strengthening its reputation among institutional and retail investors alike.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.